Oruka Therapeutics (ORKA) return on invested capital (ROIC)
Only 1 fiscal year of return on invested capital is on record here for Oruka Therapeutics (ORKA); a history needs at least 3. Figures as of 17 Nov 2026, 23:48 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on invested capital, fiscal 2025
- -70.5%
- Fiscal years on record
- 12025–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Not enough data
A history of return on invested capital needs at least 3 fiscal years; one is on record here for Oruka Therapeutics. Nothing is estimated to fill the gap. What is on record is in the table below.
Oruka Therapeutics return on invested capital (ROIC), year by year
| Fiscal year | Return on invested capital | Change | Year ended |
|---|---|---|---|
| 2025 | -70.5% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
How to read it
It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.
Return on invested capital at health care companies of similar size
| Company | Return on invested capital | Fiscal year |
|---|---|---|
| Axsome Therapeutics AXSM | -4103.5% | 2022 |
| Chemed CHE | 24.3% | 2025 |
| Oruka Therapeutics ORKA | -70.5% | 2025 |
| Arrowhead Pharmaceuticals ARWR | -3158.3% | 2024 |
| MSA Safety MSA | 16.3% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Oruka Therapeutics, figure by figure
- Oruka Therapeutics market cap
- Oruka Therapeutics revenue
- Oruka Therapeutics earnings
- Oruka Therapeutics earnings per share (EPS)
- Oruka Therapeutics P/E ratio
- Oruka Therapeutics P/S ratio
- Oruka Therapeutics P/B ratio
- Oruka Therapeutics free cash flow
- Oruka Therapeutics operating margin
- Oruka Therapeutics dividend
- Oruka Therapeutics shares outstanding
- Oruka Therapeutics total debt
- Oruka Therapeutics cash on hand
- Oruka Therapeutics total assets
- Oruka Therapeutics return on equity (ROE)
Oruka Therapeutics (ORKA) overview: price, valuation and scorecardAll health care companies by market value
Oruka Therapeutics return on invested capital (ROIC): questions and answers
How is Oruka Therapeutics's return on invested capital calculated?
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
Fiscal years are named for the calendar year they end in.
Learn: return on invested capital (ROIC)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Oruka Therapeutics (ORKA) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/ORKA/roic
Underlying data: the company's filings with the SEC and Yahoo Finance.